<- Go Home
Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Market Cap
$573.5K
Volume
56.7K
Cash and Equivalents
$2.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$11.85
52 Week Low
$0.30
Dividend
N/A
Price / Book Value
0.23
Price / Earnings
-0.02
Price / Tangible Book Value
0.23
Enterprise Value
-$3.0M
Enterprise Value / EBITDA
N/A
Operating Income
-$11.3M
Return on Equity
931.95%
Return on Assets
-311.89
Cash and Short Term Investments
$2.6M
Debt
N/A
Equity
$1.9M
Revenue
N/A
Unlevered FCF
-$7.4M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium